Joanne Livermore

F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase

Jason D. Oliver, Graham E. M. Sibley, Nicola Beckmann et al. · Proceedings of the National Academy of Sciences · 2016 · 282 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa

Tim Felton, Joanne Goodwin, Lucy O’Connor et al. · Antimicrobial Agents and Chemotherapy · 2013 · 100 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Pharmacodynamics of the Orotomides against <i>Aspergillus fumigatus</i> : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease

William Hope, Laura McEntee, Joanne Livermore et al. · mBio · 2017 · 77 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and<i>In Vitro</i>Susceptibility Breakpoints

Ajay Sudan, Joanne Livermore, Susan J. Howard et al. · Antimicrobial Agents and Chemotherapy · 2013 · 60 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus

C. E. Negri, Adam Johnson, Laura McEntee et al. · The Journal of Infectious Diseases · 2017 · 60 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17